Clinical and epidemiological features of meningococcal infection


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Objective. To study the clinical and epidemiological features of meningococcal infection (MI) in patients in Uzbekistan. Subjects and methods. The paper presents the results of a prospective study of epidemiological and clinical and laboratory data in 118patients with generalized MI (GMI) treated in the Tashkent City Clinical Infectious Diseases Hospital One during the rise of the MI epidemic in Tashkent in January-May 2019. The patients’ age was 6 months to 65 years. Results. The epidemiological situation of MI in Uzbekistan is characterized by the signs of an interepidemic period; the proportion of patients aged 7-14 (17.9%) and 20-29 (39.8%) years was high in the age structure. The main causative agent in the laboratory-confirmed cases of the disease was Neisseria meningitidis serogroup A (99.1%), while in the previous years the cases of the disease were caused by N. meningitidis serogroup W135. The characteristic hemorrhagic rash in the presence of persistent hyperthermia, which appeared only on 3-4 days of the disease, was a clinical feature of GMI, which significantly makes its timely diagnosis difficult. Convalescents who had experienced a combined form of MI and pure meningitis developed complications, such as sensorineural hearing loss (3.3%), residual encephalopathy (11.8%), and deep necroses with scarring at the site of rashes (0.8%). Conclusion. The current epidemic situation and the clinical course of GMI in the Republic of Uzbekistan require decisive preventive measures. Today, specific prevention is one of the most relevant areas in reducing the incidence of MI and death among children and adults.

Толық мәтін

Рұқсат жабық

Авторлар туралы

T. Daminov

Tashkent Medical Academy

Email: dr.daminov@mail.ru

L. Tuychiev

Tashkent Medical Academy

Email: l.tuychiev@mail.ru

N. Tadjieva

Tashkent Medical Academy; Research Institute of Epidemiology, Microbiology, and Infectious Diseases, Ministry of Health of the Republic of Uzbekistan

Email: nigora1973@list.ru. nigoratadjieva.1773@gmail.com

Z. Murtazaeva

Research Institute of Epidemiology, Microbiology, and Infectious Diseases, Ministry of Health of the Republic of Uzbekistan

Email: ziyodaxon1984@mail.ru

B. Kurbanov

Agency for Sanitary and Epidemiological Well-Being, Ministry of Health of the Republic of Uzbekistan

Email: beksardor1@rambler.ru

G. Kurbanova

City Infectious Diseases Clinical Hospital One, Tashkent

Email: gor.inf_1@minzdrav.uz

H. Magzumov

Tashkent Medical Academy

Email: info@tma.uz,tta2005@mail.ru

Әдебиет тізімі

  1. Королева И.С., Белошицкий Г.В., Королева М.А. Менингококковая инфекция и бактериальные гнойные менингиты в Российской Федерации: десятилетнее эпидемиологическое наблюдение. Эпидемиол. инфекц. болезни. Актуал. вопр. 2013; (2): 15-20
  2. Скрипченко Н.В., Вильниц А.А. Менингококковая инфекция у детей. Руководство для врачей. СПб: Тактик-Студио, 2015. 840 с
  3. Borrow R., Caugant D.A., Ceyhan M., Christensen H., Dinlyici E.C., Findlow J. et al. Meningococcal disease in the Middle East and Africa: Findings and updates from the Global Meningococcal Initiative. J. Infect. 2017; 75(1). DOI: 10.1016 / j.jinf.2017.04.007
  4. Borrow R., Lee J.S., Vizquez J.A., Enwere G., Taha M.K., Kamiya H., Kim H.M., Jo D.S. Meningococcal disease in the Asia-Pacific region: Findings and recommendations from the Global Meningococcal Initiative. Vaccine 2016; 34(48): 5855-62. doi: 10.1016/j.vaccine.2016.10.022.
  5. Sifadi M.A., O’Ryan M., Valenzuela Bravo M.T., Brandileone M.C., Gorla M.C., de Lemos A.P. et al. The current situation of meningococcal disease in Latin America and updated Global Meningococcal Initiative (GMI) recommendations. Vaccine 2015; 33(48): 6529-36. doi: 10.1016/j.vaccine.2015.10.055
  6. Li Y.A., Tssang R., Desai S., Deehan H. Enhanced Surveillance of Invasive Meningococcal Disease in Canada 2006-2011. Canada Communicable Disease Report 2014: 40(9): 160-9. http://dx.doi.org/10.14745/ccdr. v40i09a01
  7. Knol M.J., Hahn6 S.J.M., Lucidarme J., Campbell H., de Melker H.E., Gray S.J. et al. Temporal associations between national outbreaks of meningococcal serogroup W and C disease in the Netherlands and England: an observational cohort study. Lancet Public Health 2017; (10): е473-82.
  8. Ali A., Jafri R.Z., Messonnier N., Tevi-Benissan C., Durrheim D., Eskola J. et al. Global practices of meningococcal vaccine use and impact on invasive disease. Pathog. Glob. Health 2014; 108(1): 11-20. DOI: 10.1179/ 2047773214Y.0000000126.
  9. Тагаченкова Т.А., Королева М.А., Миронов К.О., Лыткина И.Н., Пяева А.П., Закроева И.М., Заикин В.Л., Соловьева Л.Я. Менингококковое носительство в очагах менингококковой инфекции. Эпидемиол. и инфекц. бол. 2009; (4): 6-10.
  10. WHO. «Bacterial Meningitis» New and Under-utilized Vaccines Implementation (NUVI) 2010. http://www.who.int/ nuvi/meningitis/en/ index.html.
  11. Centers for Disease Control and Prevention (CDC). Active Bacterial Core Surveillance (ABCs) Report Emerging Infections Program Network Neisseria meningitidis, 2016. https://www. cdc.gov/abcs/reports-findings/survreports/mening16.html
  12. Fukusumi M., Kamiya H., Takahashi H., Kanai M., Hachis u Y. , Saitoh T. et al. National surveillance for meningococcal disease in Japan, 1999-2014. Vaccine 2016; 34(34): 4068-71. https://doi.org/10.1016/j.vaccine.2016. 06.018
  13. Lahra M.M., Enriquez R.P. National Neisseria Network, Australian Meningococcal Surveillance Programme annual report, 2015. Commun Dis. Intell Q Rep. 2016; 40(4): Е503-11.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2020